Teladoc Health, Inc. (NYSE: TDOC) announced its 2022 Q2 financial results on July 27, 2022. According to the announcement, total revenue was up 18% (YoY, 3 months). On the other hand, Teladoc recorded operating loss and net loss of -3 billion USD each (3 months), due to non-cash goodwill impairment charge, which is related to the past M&A. Teledoc previously announced similar non-cash goodwill impairment in 2022 Q1.
However, adjusted EBITDA recorded 46 million USD in 2022 Q2, although it was down 30% (YoY, 3 months).
Of the total revenue, subscription based access fee revenue increased by 18% (YoY, 3 months). In 2022 Q2, the access fee revenue accounts for 88% of the total revenue and GAAP gross margin recorded 68%. These figures indicate the superiority of the business model and promising financial outlook of Teladoc.
Reviewing cashflow statement, net cash provided by operating activities was up 78% (6 months, YoY). However, free cash flow recorded outflow of 12 million USD. The main cause of the negative figure of free cash flow was the recording costs for capitalized software.
As for the visits and membership, total visit was up 28%, US paid membership was up 9%, and unique chronic care members was up 13% (YoY, 3 months). Since treatment of chronic diseases incurs continuous costs, the increase in the number of unique chronic care members may contribute to improvement of Teladoc’s business performance.
Teladoc still has cash and cash equivalents exceeding double of its total current liabilities. Thus, its financial position seems to be extremely stable.
Watanabe & Brothers’ Investment will continue to invest in Teladoc Health.
- Watanabe & Brothers’ Investment is holding shares of Teladoc Health.
- This report is provided solely for informational purpose and not intended for the purpose of soliciting investment in, or as a recommendation to purchase or sell any specific products.
- Any opinions or statements expressed in this report are based on the author’s personal and subjective views, and are not the official views of the organization to which the author belongs. In addition, although we have done our best efforts in making accurate assessments on the original financial statements, we cannot guarantee any complete accuracy of this report. We do not guarantee either that any future forecasts referred to in this report will certainly be realized. Investment in listed stocks, ETFs, etc. should be carried out under the responsibility of each investor, and even if the investor who read this report suffers a loss due to investment activities, Watanabe & Brothers’ Investment is not responsible for any liability.
- This report was originally prepared in English, and translated into the other languages with plugin utilizing Google Translation API. We hereby notify that the translations are provided only for the sake of reference, and any opinions or statements in this report should be interpreted in original English. We ask any investors reading this report to refer to the original financial statements issued by the company.